AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

What low-GWP propellants mean for inhaler design, manufacturing, and packaging.

Introduction Inhaled therapy remains the mainstay of pharmacological treatment in COPD. Sub-optimal inhaler adherence leads to poorer clinical outcomes and unnecessary escalation of treatment. There ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

AstraZeneca’s IL-33 blocker, tozorakimab has significantly reduced the annualised rate of COPD exacerbations as an adjuvant to SoC inhaled therapy over placebo in two Phase III studies. Credit: ...

In patients with COPD, transitioning from LABA/LAMA to extrafine single-inhaler triple therapy resulted in a 100 mL absolute increase in FEV 1 over 12 months. In moderate to severe chronic obstructive ...

Patients who received fluticasone furoate-vilanterol had a 9% lower risk for a first moderate or severe COPD exacerbation than those who received budesonide-formoterol (hazard ratio [HR], 0.91; 95% CI ...

Please provide your email address to receive an email when new articles are posted on . Risk for first moderate/severe COPD exacerbation was lower among dry powder vs. metered-dose or soft mist ...

The compliance rate of inhaled medication in patients with COPD is <50%, which increases the risk of acute exacerbations. Considering the complex steps of inhaled medication, improving inhaled ...

The impact of pulmonary diseases on other chronic conditions is often misunderstood and commonly underreported. More than half the Americans with Chronic Obstructive Pulmonary Disease (COPD) have not ...